Nursing Department, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Support Care Cancer. 2022 Apr;30(4):3321-3327. doi: 10.1007/s00520-021-06639-2. Epub 2022 Jan 5.
The influence of innovative chimeric antigen receptor T cell (CAR-T) therapy for hematological malignancies on nutritional status remains unknown. Therefore, we aim to explore the alterations of nutritional status after CAR-T cell therapy in patients with hematological malignancies.
We retrospectively collected the data of patients with acute leukemia (AL), lymphoma, and multiple myeloma (MM), who underwent CAR-T therapy at our hospital from 2018 to 2020. The serum albumin, triglyceride, and cholesterol before and 7, 14, and 21 days after CAR-T cell infusion were compared and analyzed.
A total of 117 patients were enrolled, consisting of 39 AL, 23 lymphoma, and 55 MM patients. The baseline albumin, triglyceride, and cholesterol were 37.43 ± 5.08 mg/L, 1.63 ± 0.74 mmol/L, and 3.62 ± 1.03 mmol/L, respectively. The lowest albumin level was found at 7 days after CAR-T cell infusion compared with baseline (P < 0.001), while the levels of triglyceride increased at 14 and 21 days (P < 0.001, P = 0.036). The levels of cholesterol at 7, 14, and 21 days after CAR-T cell infusion were lower than baseline (all P < 0.05). Spearman's correlation coefficient showed cytokine release syndrome grade was negatively correlated with the levels of albumin at 7 days and cholesterol at 21 days after CAR-T cell infusion (r = - 0.353, P < 0.001; r = - 0.395, P = 0.002).
The alterations of different nutrition-related biochemical parameters varied after CAR-T cell therapy. The levels of albumin and total cholesterol after CAR-T cell infusion were negatively correlated with the grade of cytokine release syndrome. Specific screening and intervention for malnutrition in patients receiving CAR-T cell therapy need to be explored in further studies.
嵌合抗原受体 T 细胞(CAR-T)疗法治疗血液系统恶性肿瘤对营养状况的影响尚不清楚。因此,我们旨在探讨血液系统恶性肿瘤患者接受 CAR-T 细胞治疗后营养状况的变化。
我们回顾性收集了 2018 年至 2020 年在我院接受 CAR-T 治疗的急性白血病(AL)、淋巴瘤和多发性骨髓瘤(MM)患者的数据。比较并分析了 CAR-T 细胞输注前后的血清白蛋白、甘油三酯和胆固醇水平。
共纳入 117 例患者,其中 AL 39 例、淋巴瘤 23 例、MM 55 例。基线时白蛋白、甘油三酯和胆固醇分别为 37.43±5.08mg/L、1.63±0.74mmol/L和 3.62±1.03mmol/L。CAR-T 细胞输注后第 7 天白蛋白最低,与基线相比差异有统计学意义(P<0.001),而甘油三酯水平在第 14 天和第 21 天升高(P<0.001,P=0.036)。CAR-T 细胞输注后第 7、14 和 21 天的胆固醇水平均低于基线(均 P<0.05)。Spearman 相关系数分析显示,细胞因子释放综合征(CRS)分级与 CAR-T 细胞输注后第 7 天白蛋白和第 21 天胆固醇水平呈负相关(r=-0.353,P<0.001;r=-0.395,P=0.002)。
CAR-T 细胞治疗后,不同营养相关生化参数的变化不同。CAR-T 细胞输注后白蛋白和总胆固醇水平与 CRS 分级呈负相关。需要进一步研究探索接受 CAR-T 细胞治疗的患者发生营养不良的具体筛查和干预措施。